Back to top

Image: Bigstock

Aerie Pharmaceuticals, Inc.

Read MoreHide Full Article

Aerie’s third-quarter results were disappointing with the company reporting a wider-than-expected loss. Nevertheless, we are encouraged by the company’s efforts on developing two late-stage candidates – Rhopressa and Roclatan. A potential approval and successful commercialization of the drugs will significantly boost the company’s growth prospects in the global ophthalmic market. Moreover, Aerie’s shares have outperformed that of the industry year to date. However, with no approved product in its portfolio, Aerie depends heavily on its late-stage candidates. The recent withdrawal of an NDA for Rhopressa due to product manufacturing pre-approval inspection issues was disappointing. Any such regulatory setback will have an adverse impact on the stock.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Aerie Pharmaceuticals, Inc. (AERI) - free report >>

Published in